These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17684971)

  • 41. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.
    Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS
    J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Influence of cerebrolysin therapy on the dynamics of diabetic polyneuropathy symptoms].
    Bogdanov EI; Sakovets TG; Gil'mullin IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(9):31-4. PubMed ID: 19770830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Noopept in the treatment of mild cognitive impairment in patients with stroke].
    Amelin AV; Iliukhina AIu; Shmonin AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):44-6. PubMed ID: 22500312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy of acatinol memantine in mild cognitive disorder].
    Levin OS; Iunishchenko NA; Dudarova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):36-42. PubMed ID: 19672236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cerebrolysin in the treatment of brain injuries of moderate severity].
    Talypov AE; Myachin MY; Kuksova NS; Kordonsky AY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):98-106. PubMed ID: 25591645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
    Frölich L; Ashwood T; Nilsson J; Eckerwall G;
    J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy of actovegin in the treatment of elderly patients with vascular mild cognitive impairment].
    Mikhaĭlova NM; Selezneva ND; Kalyn IaB; Roshchina IF; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):69-76. PubMed ID: 23994934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
    Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of drugs against dementia on cognition in aging and mild cognitive impairment.
    Ihl R
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S38-43. PubMed ID: 13130387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Experience with using high doses of cerebrolysin in vascular dementia].
    Iakhno NN; Damulin IV; Zakharov VV; Levin OS; Elkin MN
    Ter Arkh; 1996; 68(10):65-9. PubMed ID: 9026950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subcortical vascular cognitive impairment, no dementia: EEG global power independently predicts vascular impairment and brain symmetry index reflects severity of cognitive decline.
    Sheorajpanday RV; Mariën P; Nagels G; Weeren AJ; Saerens J; van Putten MJ; De Deyn PP
    J Clin Neurophysiol; 2014 Oct; 31(5):422-8. PubMed ID: 25271680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Use of omaron in patients with post-stroke cognitive disorders].
    Parfenov VA; Belavina GR; Vakhnina NV; Gusev VV; Levin IaI; Markin SP; Starchina IuA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(6):41-5. PubMed ID: 19672226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
    Chételat G; Eustache F; Viader F; De La Sayette V; Pélerin A; Mézenge F; Hannequin D; Dupuy B; Baron JC; Desgranges B
    Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
    Wesnes KA; McKeith I; Edgar C; Emre M; Lane R
    Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progressive gray matter atrophy in lacunar patients with vascular mild cognitive impairment.
    Grau-Olivares M; Arboix A; Junqué C; Arenaza-Urquijo EM; Rovira M; Bartrés-Faz D
    Cerebrovasc Dis; 2010; 30(2):157-66. PubMed ID: 20551631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
    Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
    Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial.
    Ladurner G; Kalvach P; Moessler H;
    J Neural Transm (Vienna); 2005 Mar; 112(3):415-28. PubMed ID: 15583955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.